GLP-1 receptor agonists have transformed weight loss treatment over the past decade, with clinical trials showing average weight reductions of 15-22% depending on the medication and dose
Unfortunately, for many patients, its not that simple
But they look different when placed next to what came later
Within 2 years after transjugular intrahepatic portosystemic shunt (TIPS) placement, the incidence of HE ranges from 20 to 55%
As one user put it: "As Ive lost weight Ive definitely noticed the cold and the aches being fat is great for bones in that we are less likely to suffer from osteoporosis as when you are fat you naturally are hauling around the weight so built in strength training." - u/SJP-NYC "Bone and muscle loss are normal with weight loss
At launch, they might not be significantly cheaper if the technology involved in oral delivery is still expensive to produce. This will impact the industry tremendously Of course, if FDA approved, GLP-1 pills could drastically open up the market for these kinds of therapies
